Founded in 2018, Shorla Oncology focuses on formulating and commercialising oncology drugs for therapeutic areas that have been historically underserved, with a particular emphasis on paediatric and other rare cancers. The company operates dual headquarters in Clonmel, Co Tipperary and Cambridge, Massachusetts, reflecting its Irish origins and expanding U.S. presence. Shorla’s pipeline targets gaps left by larger pharmaceutical firms, aiming to bring new, patient-centred options to market. Its mission and progress earned co-founders Sharon Cunningham and Orlaith Ryan the 2024 EY Entrepreneur of the Year award. Financially, Shorla has now raised more than $60 million in total funding, enabling continued R&D and commercial growth. The latest capital injection positions the company to advance additional oncology candidates and strengthen its transatlantic market reach.

Total raised

$56M

Funding rounds

2

Latest round

Equity

Latest activity

Jan 2026